+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

North America Neutropenia Treatment Market By Distribution channel, By Treatment, By Country, Industry Analysis and Forecast, 2020 - 2026

  • ID: 5129436
  • Report
  • June 2020
  • Region: North America
  • 61 Pages
  • Marqual IT Solutions Pvt. Ltd (KBV Research)

FEATURED COMPANIES

  • Amgen, Inc.
  • BeyondSpring, Inc.
  • Mylan N.V.
  • Novartis AG
  • Pfizer, Inc.
The North America Neutropenia Treatment Market is expected to witness market growth of 5.5% CAGR during the forecast period (2020-2026).

Neutropenia can compromise optimal cancer treatment by increasing, delaying, or even discontinuing the dose of chemotherapy. Such dose modifications are often made during the initial stages of chemotherapy, as neutropenic symptoms frequently occur early in the process of chemotherapy. Treatment response often depends on the delivery of standard chemotherapy doses, and changes in dosing may threaten complete response rates and reduce survival. Caregivers, therefore, face the challenge of maintaining adequate chemotherapy doses while managing neutropenic complications. The evaluation of chemotherapy-induced neutropenia is gaining significance.

Children often experience fever with severe neutropenia. They are given antibiotics to combat infection as they do, so they will need to be Retailized. Repeated use of antibiotics can, however, have side effects such as the production of drug-resistant bacteria, diarrhea or enterocolitis, and inflammation of the intestines. Some antibiotics may have adverse effects on the function of the kidney and liver.

New medications have been designed to support the bone marrow to produce neutrophils and improve the body's protection against infection. These drugs are referred to as granulocyte colony-stimulating factors. They help keep neutrophils in the blood above the level of danger all or most of the time. The shorter the time the neutrophil count is low, the less likely your child will develop a fever or infection. These drugs can reduce the amount and seriousness of infections and reduce Retailizations.

Based on Distribution channel, the market is segmented into Retail pharmacies, Hospital pharmacies and Online pharmacies. Based on Treatment, the market is segmented into Colony-stimulating factor, Antibiotics, Antifungals and Antivirals. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Amgen, Inc., Novartis AG, Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., BeyondSpring, Inc., Spectrum Pharmaceuticals, Inc., Kyowa Kirin Co., Ltd. (Kirin Company), Mylan N.V., Cellerant Therapeutics, Inc., and Partner Therapeutics, Inc.

Scope of the Study

Market Segmentation:

By Distribution Channel
  • Retail pharmacies
  • Hospital pharmacies and
  • Online pharmacies

By Treatment
  • Colony-stimulating factor
  • Antibiotics
  • Antifungals and
  • Antivirals

By Country
  • US
  • Canada
  • Mexico
  • Rest of North America

Companies Profiled
  • Amgen, Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Teva Pharmaceuticals Industries Ltd.
  • BeyondSpring, Inc.
  • Spectrum Pharmaceuticals, Inc.
  • Kyowa Kirin Co., Ltd. (Kirin Company)
  • Mylan N.V.
  • Cellerant Therapeutics, Inc.
  • Partner Therapeutics, Inc.

Unique Offerings from the Publisher
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Amgen, Inc.
  • BeyondSpring, Inc.
  • Mylan N.V.
  • Novartis AG
  • Pfizer, Inc.

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Neutropenia Treatment Market, by Distribution Channel
1.4.2 North America Neutropenia Treatment Market, by Treatment
1.4.3 North America Neutropenia Treatment Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. North America Neutropenia Treatment Market by Distribution channel
3.1 North America Retail pharmacies Market by Country
3.2 North America Hospital pharmacies Market by Country
3.3 North America Online pharmacies Market by Country
Chapter 4. North America Neutropenia Treatment Market by Treatment
4.1 North America Colony-stimulating factor Market by Country
4.2 North America Antibiotics Market by Country
4.3 North America Antifungals Market by Country
4.4 North America Antivirals Market by Country
Chapter 5. North America Neutropenia Treatment Market by Country
5.1 US Neutropenia Treatment Market
5.1.1 US Neutropenia Treatment Market by Distribution channel
5.1.2 US Neutropenia Treatment Market by Treatment
5.2 Canada Neutropenia Treatment Market
5.2.1 Canada Neutropenia Treatment Market by Distribution channel
5.2.2 Canada Neutropenia Treatment Market by Treatment
5.3 Mexico Neutropenia Treatment Market
5.3.1 Mexico Neutropenia Treatment Market by Distribution channel
5.3.2 Mexico Neutropenia Treatment Market by Treatment
5.4 Rest of North America Neutropenia Treatment Market
5.4.1 Rest of North America Neutropenia Treatment Market by Distribution channel
5.4.2 Rest of North America Neutropenia Treatment Market by Treatment
Chapter 6. Company Profiles
6.1 Amgen, Inc.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Research & Development Expense
6.2 Novartis AG
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Recent strategies and developments:
6.2.4.1 Approvals:
6.3 Pfizer, Inc.
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Recent strategies and developments:
6.3.4.1 Approvals:
6.3.4.2 Acquisition and Mergers:
6.4 Teva Pharmaceutical Industries Ltd.
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional Analysis
6.4.4 Research & Development Expenses
6.4.5 Recent strategies and developments:
6.4.5.1 Partnerships, Collaborations, and Agreements:
6.5 BeyondSpring, Inc.
6.5.1 Company Overview
6.6 Spectrum Pharmaceuticals, Inc.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Research & Development Expenses
6.7 Kyowa Kirin Co., Ltd. (Kirin Company)
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Regional Analysis
6.7.4 Research & Development Expense
6.8 Mylan N.V.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Regional Analysis
6.8.4 Research & Development Expense
6.8.5 Recent strategies and developments:
6.8.5.1 Partnerships, Collaborations, and Agreements:
6.9 Cellerant Therapeuticsc, Inc.
6.9.1 Company Overview
6.9.2 Recent strategies and developments:
6.9.2.1 Approvals:
6.10 Partner Therapeutics, Inc.
6.10.1 Company overview
6.10.2 Recent strategies and developments:
6.10.2.1 Partnerships, Collaborations, and Agreements:
6.10.2.2 Approvals:
Note: Product cover images may vary from those shown
  • Amgen, Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Teva Pharmaceuticals Industries Ltd.
  • BeyondSpring, Inc.
  • Spectrum Pharmaceuticals, Inc.
  • Kyowa Kirin Co., Ltd. (Kirin Company)
  • Mylan N.V.
  • Cellerant Therapeutics, Inc.
  • Partner Therapeutics, Inc.
Note: Product cover images may vary from those shown

Loading
LOADING...